Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

AZD 6244 × Genitourinary × 90 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 9 Thoracic 2 Tumor-Agnostic 1 Sarcoma 1 Other hematologic neoplasm 1 Myeloid 1 Genitourinary 1 Dermatologic 1 Breast 1

Conditions

Muscle Invasive Bladder Cancer 1

Interventions

Magnetic Resonance Spectroscopy 90 Specimen Handling 88 pembrolizumab 75 enzalutamide 57 Nivolumab 49 Prednisone 47 Gemcitabine 44 Docetaxel 44 Abiraterone Acetate 42 apalutamide 39 Androgen Antagonists 39 Biopsy 37 Radiosurgery 36 Radiotherapy 35 darolutamide 33 Cisplatin 32 Carboplatin 31 Leuprolide 30 Ipilimumab 30 cabozantinib 28 enfortumab vedotin 27 abiraterone 25 X-Rays 23 Radiation 23 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 21 atezolizumab 20 Pluvicto 20 Goserelin 19 relugolix 17 cabazitaxel 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02546661 2025-12-29

BISCAY

AstraZeneca

Phase 1 Active not recruiting

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡